TOKYO, May 18 (Pulse News Wire) – Prism Biolab Co.,ltd (206A.T) reported an interim loss of ¥833 million for the six months ending September 2026, compared to ¥474 million in the same period last year. Revenue increased to ¥677 million from ¥305 million, while operating losses narrowed slightly to ¥774 million from ¥782 million.
The company's hit creation programs continued to advance, achieving two hits through high-throughput screening (HTS). Four programs were initiated in the first half of fiscal 2026, meeting its target of ten programs annually.
Additionally, PRISM BioLab completed Phase I/IIa clinical trials for PRI-724, demonstrating significant improvements in liver hardness and function among patients with hepatitis C and B virus-induced liver cirrhosis. In collaboration with Eisai, the company reached proof-of-concept (POC) milestones for its CREB-binding protein (CBP)/β-catenin interaction inhibitor E7386, showing promising preliminary antitumor activity in endometrial cancer patients.
The ongoing Phase II trial aims to secure approval by March 2031.
🟢 Confidence: High AI-translated content.